Imugene Reports 83% Overall Response Rate From CAR T-Naive Niche Indication Portion of B-Cell Lymphoma Drug Candidate Trial, Shares Up 7%

MT Newswires Live

Oct 29, 2025

Imugene (ASX:IMU) said data from its phase 1b clinical trial evaluating the azer-cel drug candidate in patients with B-cell lymphoma showed an overall response rate of 83% in six evaluable heavily pretreated chimeric antigen receptor (CAR) T-naïve patients in the CAR T-naive niche indication portion of the trial, according to a Monday Australian bourse filing.

Three out of the six patients reported a complete response. A total of ten patients have been treated in the cohort thus far.

The firm's shares rose 7% in recent trading on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2579294245"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579294245\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579294245?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-29 13:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579294245","market":"fut","top_or_hot":-1,"title":"Imugene Reports 83% Overall Response Rate From CAR T-Naive Niche Indication Portion of B-Cell Lymphoma Drug Candidate Trial, Shares Up 7%","media":"MT Newswires Live","content":"<html><body><p> Imugene (ASX:IMU) said data from its phase 1b clinical trial evaluating the azer-cel drug candidate in patients with B-cell lymphoma showed an overall response rate of 83% in six evaluable heavily pretreated chimeric antigen receptor (CAR) T-naïve patients in the CAR T-naive niche indication portion of the trial, according to a Monday Australian bourse filing.</p><p>Three out of the six patients reported a complete response. A total of ten patients have been treated in the cohort thus far.</p><p>The firm's shares rose 7% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Imugene Reports 83% Overall Response Rate From CAR T-Naive Niche Indication Portion of B-Cell Lymphoma Drug Candidate Trial, Shares Up 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImugene Reports 83% Overall Response Rate From CAR T-Naive Niche Indication Portion of B-Cell Lymphoma Drug Candidate Trial, Shares Up 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-29 13:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Imugene (ASX:IMU) said data from its phase 1b clinical trial evaluating the azer-cel drug candidate in patients with B-cell lymphoma showed an overall response rate of 83% in six evaluable heavily pretreated chimeric antigen receptor (CAR) T-naïve patients in the CAR T-naive niche indication portion of the trial, according to a Monday Australian bourse filing.</p><p>Three out of the six patients reported a complete response. A total of ten patients have been treated in the cohort thus far.</p><p>The firm's shares rose 7% in recent trading on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CAR","symbol_name":"安飞士","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2579294245","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579294245","pubTimestamp":1761714101,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Imugene  said data from its phase 1b clinical trial evaluating the azer-cel drug candidate in patients with B-cell lymphoma showed an overall response rate of 83% in six evaluable heavily pretreated chimeric antigen receptor  T-nave patients in the CAR T-naive niche indication portion of the trial, according to a Monday Australian bourse filing.Three out of the six patients reported a complete response. A total of ten patients have been treated in the cohort thus far.The firm's shares rose 7% in recent trading on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CAR":"安飞士","BK4022":"陆运","BK4230":"旅客陆运","BK7503":"科技股","IMU.AU":"IMUGENE LTD","BK7002":"互动媒体与服务","CAR.AU":"CAR GROUP LTD","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"Imugene报告B细胞淋巴瘤候选药物试验的CAR T幼稚利基适应症部分的总体缓解率为83%，股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAR.AU":1,"CAR":1.5,"IMU.AU":1},"content_text":"Imugene (ASX:IMU) said data from its phase 1b clinical trial evaluating the azer-cel drug candidate in patients with B-cell lymphoma showed an overall response rate of 83% in six evaluable heavily pretreated chimeric antigen receptor (CAR) T-naïve patients in the CAR T-naive niche indication portion of the trial, according to a Monday Australian bourse filing.Three out of the six patients reported a complete response. A total of ten patients have been treated in the cohort thus far.The firm's shares rose 7% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}